CA2915027A1 - Compositions et procedes d'administration de vaccins contre le virus de la dengue - Google Patents

Compositions et procedes d'administration de vaccins contre le virus de la dengue Download PDF

Info

Publication number
CA2915027A1
CA2915027A1 CA2915027A CA2915027A CA2915027A1 CA 2915027 A1 CA2915027 A1 CA 2915027A1 CA 2915027 A CA2915027 A CA 2915027A CA 2915027 A CA2915027 A CA 2915027A CA 2915027 A1 CA2915027 A1 CA 2915027A1
Authority
CA
Canada
Prior art keywords
dengue virus
administration
compositions
methods
vaccines against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2915027A
Other languages
English (en)
Inventor
Dan T. Stinchcomb
Jorge E. Osorio
Charalambos D. Partidos
Joseph N. Brewoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/492,884 external-priority patent/US8968996B2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CA2915027A1 publication Critical patent/CA2915027A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2915027A 2012-06-10 2013-06-10 Compositions et procedes d'administration de vaccins contre le virus de la dengue Abandoned CA2915027A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/492,884 2012-06-10
US13/492,884 US8968996B2 (en) 2009-06-01 2012-06-10 Compositions and methods for rapid immunization against dengue virus
PCT/US2013/045041 WO2013188315A1 (fr) 2012-06-10 2013-06-10 Compositions et procédés d'administration de vaccins contre le virus de la dengue

Publications (1)

Publication Number Publication Date
CA2915027A1 true CA2915027A1 (fr) 2013-12-19

Family

ID=48652375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2915027A Abandoned CA2915027A1 (fr) 2012-06-10 2013-06-10 Compositions et procedes d'administration de vaccins contre le virus de la dengue

Country Status (6)

Country Link
EP (1) EP2858668A1 (fr)
JP (2) JP2015520196A (fr)
CA (1) CA2915027A1 (fr)
NZ (1) NZ630831A (fr)
TW (1) TW201402143A (fr)
WO (1) WO2013188315A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093182A1 (fr) 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, procédés d'administration et utilisations de formulations trivalentes contre le virus de la dengue
CN113637694A (zh) 2013-03-15 2021-11-12 武田疫苗股份有限公司 用于疫苗中的登革热病毒嵌合式构建物的组合物及方法
CA2991212A1 (fr) * 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions et procedes pour polytherapie utilisant le virus de la dengue et des cellules dendritiques
CA2999881A1 (fr) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions et procedes pour produire des cellules dendritiques
EP3442571A1 (fr) * 2016-04-13 2019-02-20 Takeda Vaccines, Inc. Compositions et procédés de vaccination contre le virus de la dengue chez des enfants et de jeunes adultes
TWI625393B (zh) * 2016-11-15 2018-06-01 國立清華大學 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
CA3049225A1 (fr) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions et methodes de therapie avec le virus de la dengue
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110196B2 (en) * 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2010141386A1 (fr) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions et procédés destinés à l'administration de vaccins contre le virus de la dengue
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus

Also Published As

Publication number Publication date
EP2858668A1 (fr) 2015-04-15
JP2015520196A (ja) 2015-07-16
JP2018090618A (ja) 2018-06-14
TW201402143A (zh) 2014-01-16
NZ630831A (en) 2019-02-22
WO2013188315A1 (fr) 2013-12-19

Similar Documents

Publication Publication Date Title
CA2915027A1 (fr) Compositions et procedes d'administration de vaccins contre le virus de la dengue
EP4357355A3 (fr) Purification de virus
HK1259355A1 (zh) 作為btk激酶抑制劑的2，3-二氫異吲哚-1-酮衍生物、以及含有所述衍生物的藥物組合物
EP2471926A3 (fr) Oligodésoxynucléotides immunostimulateurs
WO2011103453A3 (fr) Vaccins destinés à être utilisés pour la prophylaxie et le traitement d'une maladie liée au virus de la grippe
WO2014205389A8 (fr) Modulateurs de transport nucléaire et leurs utilisations
CL2014003171A1 (es) Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica.
JP2012143233A5 (fr)
WO2012024621A3 (fr) Vaccins à nanosupport synthétique comprenant des peptides obtenus ou dérivés de l'hémagglutinine du virus de la grippe a humaine
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
WO2013170068A3 (fr) Modulateurs du transport nucléaire et leurs utilisations
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
MX2021013109A (es) Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
EP2931310A4 (fr) Compositions, procédés d'administration et utilisations de formulations trivalentes contre le virus de la dengue
WO2015173701A3 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
IN2015DN02335A (fr)
WO2014140166A3 (fr) Vaccin
EP2551266A4 (fr) Composés non nucléosidiques de 2',2-dithiazole, leurs procédés de préparation, compositions pharmaceutiques et utilisations en tant qu'inhibiteurs de virus de l'hépatite
WO2016141320A3 (fr) Virus non neuro-invasifs et leurs utilisations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151210

FZDE Dead

Effective date: 20200831